Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced on September 17 that it completed its acquisition of Marea Therapeutics and signed a definitive agreement for a concurrent private placement expected to raise approximately $225 million gross. Financing completion was expected on September 18, subject to customary closing conditions. Following both transactions, legacy equity holders of Lisata Therapeutics, Inc. (NASDAQ:LSTA) would retain approximately 2.39% ownership on the stated fully diluted, as-converted basis.
That calculation uses the treasury stock method and excludes beneficial ownership limits. Existing investors are receiving exposure to a substantially different pipeline through a much smaller proportional stake. Lisata Therapeutics, Inc. (NASDAQ:LSTA) projects that the financing will support operations into 2028.
Management expects fourth-quarter 2027 data from the MAR001 Phase 2b study in severe hypertriglyceridemia, or very high triglyceride levels, and the MAR002 Phase 2 program in acromegaly, a disorder involving excess growth hormone. The projected funding period extends beyond those planned results. For Lisata Therapeutics, Inc. (NASDAQ:LSTA), that alignment between funding and clinical milestones is the strongest argument for the transaction.
Completing patient studies could provide evidence to assess whether the acquired medicines warrant larger trials and further investment. Having resources available through expected results could also reduce pressure to seek capital before the programs produce meaningful data. Two programs offer separate opportunities to establish clinical value.
Successful results could support development partnerships or improve the terms of future financing. Those possibilities make the acquired assets and available capital central to assessing what the retained ownership might ultimately be worth. The dilution at Lisata Therapeutics, Inc. (NASDAQ:LSTA) is substantial.
On the disclosed basis, former Marea equity holders would own approximately 59.54%, while private-placement investors would own approximately 38.07%. Legacy investors therefore depend on the combined business becoming valuable enough to make their small remaining interest economically meaningful. The ownership percentages alone cannot settle that valuation question.
Extract — continue reading at the source.
